metronidazole has been researched along with Disease Exacerbation in 43 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mice were treated with broad-spectrum antibiotics or metronidazole, subjected to surgically-induced endometriosis and assayed after 21 days." | 7.91 | Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota. ( Chadchan, SB; Cheng, M; Kommagani, R; Mysorekar, IU; Parnell, LA; Schriefer, A; Yin, Y, 2019) |
| "This study aimed to develop pH-responsive polylactide-glycolic acid co-polymer and chitosan (PLGA/chitosan) nanosphere as an inflammation-responsive vehicle and evaluate the potential of the nanosphere encapsulating metronidazole, an antibiotic, and N-phenacylthiazolium bromide (PTB), a host modulator, for treating periodontitis." | 7.88 | Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide. ( Chang, PC; Feng, F; Lin, JH; Wang, CH; Yu, MC, 2018) |
| "To assess the effectiveness and tolerance of systemic metronidazole in the treatment of childhood ocular and cutaneous rosacea." | 7.77 | [Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population]. ( Aitali, F; Boralevi, F; Chamaillard, M; Colin, J; Léauté-Labrèze, C; Léoni, S; Marques da Costa, C; Mesplié, N; Mortemousque, B; Taïeb, A, 2011) |
| "This prospective, randomized, double-blind, placebo-controlled multi-centre trial comprising patients suffering from moderate to severe periodontitis evaluated the impact of rational adjunctive use of systemic amoxicillin 500 mg plus metronidazole 400 mg (3x/day, 7 days) on attachment loss." | 5.20 | Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial. ( Doering, S; Ehmke, B; Eickholz, P; Gravemeier, M; Harks, I; Harmsen, D; Hoffmann, T; Holtfreter, B; Kaner, D; Kim, TS; Koch, R; Kocher, T; Meyle, J; Schlagenhauf, U, 2015) |
| "Mice were treated with broad-spectrum antibiotics or metronidazole, subjected to surgically-induced endometriosis and assayed after 21 days." | 3.91 | Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota. ( Chadchan, SB; Cheng, M; Kommagani, R; Mysorekar, IU; Parnell, LA; Schriefer, A; Yin, Y, 2019) |
| "This study aimed to develop pH-responsive polylactide-glycolic acid co-polymer and chitosan (PLGA/chitosan) nanosphere as an inflammation-responsive vehicle and evaluate the potential of the nanosphere encapsulating metronidazole, an antibiotic, and N-phenacylthiazolium bromide (PTB), a host modulator, for treating periodontitis." | 3.88 | Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide. ( Chang, PC; Feng, F; Lin, JH; Wang, CH; Yu, MC, 2018) |
| "To assess the effectiveness and tolerance of systemic metronidazole in the treatment of childhood ocular and cutaneous rosacea." | 3.77 | [Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population]. ( Aitali, F; Boralevi, F; Chamaillard, M; Colin, J; Léauté-Labrèze, C; Léoni, S; Marques da Costa, C; Mesplié, N; Mortemousque, B; Taïeb, A, 2011) |
| " With only partial compliance to local debridement, chlorhexidine oral rinses, and systemic metronidazole therapy, alveolar bone loss resulted in tooth mobility necessitating extraction of 2 involved teeth." | 3.70 | Rapid progression of bone loss in HIV-associated necrotizing ulcerative stomatitis. ( McKaig, R; Patton, LL, 1998) |
| "In this study, periodontal disease progression was successfully arrested in 95% of the initially compromised lesions, while 2% to 5% experienced discrete or recurrent episodes of loss of periodontal support." | 2.70 | Aggressive periodontitis: 5-year follow-up of treatment. ( Buchmann, R; Lange, DE; Nunn, ME; Van Dyke, TE, 2002) |
| "Twenty adult patients with untreated periodontitis and subgingival colonization of A." | 2.69 | Clonal infection with Actinobacillus actinomycetemcomitans following periodontal therapy. ( Beikler, T; Ehmke, B; Flemmig, TF; Karch, H; Klaiber, B; Kopp, C; Schmidt, H, 1999) |
| " We aimed to compare interventions in terms of patient mortality or liver transplantation (MOLT), progression of liver histological stage (POLHS), serum bilirubin, alkaline phosphatase (ALP) levels and adverse events (AE)." | 2.52 | A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. ( Braddock, M; Chen, YP; Huang, GQ; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH; Zhou, MT; Zhu, GQ, 2015) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.50 | Topical agents and dressings for fungating wounds. ( Adderley, UJ; Holt, IG, 2014) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.44 | Topical agents and dressings for fungating wounds. ( Adderley, U; Smith, R, 2007) |
| "Rosacea is a chronic, cutaneous vascular disorder that affects approximately 13 million Americans." | 2.41 | Identifying and treating rosacea. ( Cuevas, T, 2001) |
| "Rosacea is an age-related disorder of the central portion of the facial skin whose peak onset occurs in persons in their 40s and 50s." | 2.40 | Rosacea: how to recognize and treat an age-related skin disease. ( Litt, JZ, 1997) |
| "Likewise, all three therapies attenuated alveolar bone loss." | 1.51 | Periodontal treatment prevents arthritis in mice and methotrexate ameliorates periodontal bone loss. ( Bull, J; Ebbers, MNB; Engelmann, R; Kneitz, S; Kreikemeyer, B; Lang, H; Lübcke, PM; Müller-Hilke, B; Volzke, J, 2019) |
| "We report an unusual presentation of pulmonary embolism (PE) where a 58-year-old man first developed symptoms of community-acquired pneumonia." | 1.48 | An unusual presentation of pulmonary embolism leading to infarction, cavitation, abscess formation and bronchopleural fistulation. ( Banerjee, A; Bennett, L; Morelli, T; Teng, E, 2018) |
| "Here, we report a case of an amoebic liver abscess (ALA) successfully treated with endoscopic ultrasound (EUS)-guided liver abscess drainage (EUS-LAD)." | 1.42 | Endoscopic ultrasound-guided drainage of an amoebic liver abscess extending into the hepatic subcapsular space. ( Egashira, H; Ichita, C; Kako, M; Kimbara, T; Koizumi, K; Masuda, S; Sasaki, A; Tokoro, S; Uojima, H, 2015) |
| "Moreover, the interruption of the disease progression after the antibiotic therapy is difficult to ignore without claiming that this association is at least suggestive." | 1.42 | Parry-Romberg syndrome: a case with a possible association with Lyme disease. ( di Meo, N; Nan, K; Pinzani, C; Stinco, G; Trevisan, G, 2015) |
| "Lemierre's syndrome is a rare disease in young otherwise healthy people showing septic embolism in the lungs and peripheral vessels." | 1.36 | [Phlegmon of the palm of the hand as initial manifestation of the Lemierre syndrome]. ( Braunbeck, A; Daecke, W; Fiebig, C; Geiger, EV; Maier, M; Marzi, I; Weber, R, 2010) |
| "When located in the face necrotizing fasciitis is associated with severe cosmetic and functional restrictions due to the invasive infection and often to the necessary surgical treatment." | 1.35 | Management of facial necrotizing fasciitis. ( Burghartz, M; Hoang, N; Kesting, M; Miethke, T; Schurr, C; Staudenmaier, R, 2009) |
| "Continued disease progression characterised these patients who, nevertheless, mounted an immune response to the periodontal pathogens but this appeared to be inadequate to stop the disease." | 1.29 | Putative periodontal pathogens, antibody titres and avidities to them in a longitudinal study of patients with resistant periodontitis. ( Holbrook, WP; Kinane, DF; Kitsiou, N; Mooney, J; Sigurdsson, T, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (16.28) | 18.2507 |
| 2000's | 16 (37.21) | 29.6817 |
| 2010's | 19 (44.19) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, J | 1 |
| Neill, B | 1 |
| Whitsitt, J | 1 |
| Rajpara, A | 1 |
| Aires, D | 1 |
| Lin, JH | 1 |
| Feng, F | 1 |
| Yu, MC | 1 |
| Wang, CH | 1 |
| Chang, PC | 1 |
| Teng, E | 1 |
| Bennett, L | 1 |
| Morelli, T | 1 |
| Banerjee, A | 1 |
| Mannioui, A | 1 |
| Zalc, B | 1 |
| Chadchan, SB | 1 |
| Cheng, M | 1 |
| Parnell, LA | 1 |
| Yin, Y | 1 |
| Schriefer, A | 1 |
| Mysorekar, IU | 1 |
| Kommagani, R | 1 |
| Lübcke, PM | 1 |
| Ebbers, MNB | 1 |
| Volzke, J | 1 |
| Bull, J | 1 |
| Kneitz, S | 1 |
| Engelmann, R | 1 |
| Lang, H | 1 |
| Kreikemeyer, B | 1 |
| Müller-Hilke, B | 1 |
| Faveri, M | 1 |
| Rebello, A | 1 |
| de Oliveira Dias, R | 1 |
| Borges-Junior, I | 1 |
| Duarte, PM | 1 |
| Figueiredo, LC | 1 |
| Feres, M | 1 |
| Adderley, UJ | 1 |
| Holt, IG | 1 |
| Koizumi, K | 1 |
| Masuda, S | 1 |
| Uojima, H | 1 |
| Ichita, C | 1 |
| Tokoro, S | 1 |
| Sasaki, A | 1 |
| Egashira, H | 1 |
| Kimbara, T | 1 |
| Kako, M | 1 |
| Harks, I | 1 |
| Koch, R | 1 |
| Eickholz, P | 1 |
| Hoffmann, T | 1 |
| Kim, TS | 1 |
| Kocher, T | 1 |
| Meyle, J | 1 |
| Kaner, D | 2 |
| Schlagenhauf, U | 1 |
| Doering, S | 1 |
| Holtfreter, B | 1 |
| Gravemeier, M | 1 |
| Harmsen, D | 1 |
| Ehmke, B | 2 |
| Zhu, GQ | 1 |
| Shi, KQ | 1 |
| Huang, GQ | 1 |
| Wang, LR | 1 |
| Lin, YQ | 1 |
| Braddock, M | 1 |
| Chen, YP | 1 |
| Zhou, MT | 1 |
| Zheng, MH | 1 |
| Luo, LJ | 1 |
| Li, X | 1 |
| Yang, KD | 1 |
| Lu, JY | 1 |
| Li, LQ | 1 |
| di Meo, N | 1 |
| Stinco, G | 1 |
| Nan, K | 1 |
| Pinzani, C | 1 |
| Trevisan, G | 1 |
| Ferreira, C | 1 |
| Soares, J | 1 |
| Maia, T | 1 |
| Pardal, J | 1 |
| Nogueira, A | 1 |
| Tavares, M | 1 |
| Trindade, E | 1 |
| Amil Dias, J | 1 |
| Schurr, C | 1 |
| Burghartz, M | 1 |
| Miethke, T | 1 |
| Kesting, M | 1 |
| Hoang, N | 1 |
| Staudenmaier, R | 1 |
| Amar, S | 1 |
| Wu, SC | 1 |
| Madan, M | 1 |
| Braunbeck, A | 1 |
| Geiger, EV | 1 |
| Weber, R | 1 |
| Maier, M | 1 |
| Daecke, W | 1 |
| Fiebig, C | 1 |
| Marzi, I | 1 |
| Sahaya, K | 1 |
| Sarwal, A | 1 |
| Lanigar, S | 1 |
| Miller, DC | 1 |
| Bernimoulin, JP | 1 |
| Dietrich, T | 1 |
| Kleber, BM | 1 |
| Friedmann, A | 1 |
| Léoni, S | 1 |
| Mesplié, N | 1 |
| Aitali, F | 1 |
| Chamaillard, M | 1 |
| Boralevi, F | 1 |
| Marques da Costa, C | 1 |
| Taïeb, A | 1 |
| Léauté-Labrèze, C | 1 |
| Colin, J | 1 |
| Mortemousque, B | 1 |
| Vaishnavi, C | 1 |
| Agrawal, P | 1 |
| Gandhi, V | 1 |
| Nagral, A | 1 |
| Nagral, S | 1 |
| Zätterstrøm, UK | 1 |
| Hokland, BM | 1 |
| Walberg, M | 1 |
| Stubhaug, A | 1 |
| Aaløkken, TM | 1 |
| Frøland, SS | 1 |
| Pépin, J | 1 |
| Valiquette, L | 1 |
| Alary, ME | 1 |
| Villemure, P | 1 |
| Pelletier, A | 1 |
| Forget, K | 1 |
| Pépin, K | 1 |
| Chouinard, D | 1 |
| Lindow, KB | 1 |
| Chen, LT | 1 |
| Lin, JT | 1 |
| Tai, JJ | 1 |
| Chen, GH | 1 |
| Yeh, HZ | 1 |
| Yang, SS | 1 |
| Wang, HP | 1 |
| Kuo, SH | 1 |
| Sheu, BS | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Wang, TE | 1 |
| Wu, CW | 1 |
| Chen, CL | 1 |
| Su, IJ | 1 |
| Whang-Peng, J | 1 |
| Cheng, AL | 1 |
| Adderley, U | 1 |
| Smith, R | 1 |
| Masmoudi, A | 1 |
| Boudaya, S | 1 |
| Ayadi, N | 1 |
| Bouassida, S | 1 |
| Khabir, A | 1 |
| Meziou, TJ | 1 |
| Akrout, F | 1 |
| Sallemi, T | 1 |
| Turki, H | 1 |
| Zahaf, A | 1 |
| Mättö, J | 1 |
| Saarela, M | 1 |
| von Troil-Lindén, B | 1 |
| Könönen, E | 1 |
| Jousimies-Somer, H | 1 |
| Torkko, H | 1 |
| Alaluusua, S | 1 |
| Asikainen, S | 1 |
| Holbrook, WP | 1 |
| Mooney, J | 1 |
| Sigurdsson, T | 1 |
| Kitsiou, N | 1 |
| Kinane, DF | 2 |
| Litt, JZ | 1 |
| Patton, LL | 1 |
| McKaig, R | 1 |
| Huang, FC | 1 |
| Chang, MH | 1 |
| Hsu, HY | 1 |
| Lee, PI | 1 |
| Shun, CT | 1 |
| Worch, KP | 2 |
| Listgarten, MA | 2 |
| Schmidt, H | 1 |
| Beikler, T | 1 |
| Kopp, C | 1 |
| Karch, H | 1 |
| Klaiber, B | 1 |
| Flemmig, TF | 1 |
| López, NJ | 1 |
| Gamonal, JA | 1 |
| Martinez, B | 1 |
| De Vree, H | 1 |
| Steenackers, K | 1 |
| De Boever, JA | 1 |
| Diniz, CG | 1 |
| Cara, DC | 1 |
| Nicoli, JR | 1 |
| Farias, LD | 1 |
| De Carvalho, MA | 1 |
| Korostoff, JM | 1 |
| Serino, G | 1 |
| Rosling, B | 1 |
| Ramberg, P | 1 |
| Hellström, MK | 1 |
| Socransky, SS | 1 |
| Lindhe, J | 1 |
| Cuevas, T | 1 |
| Buchmann, R | 1 |
| Nunn, ME | 1 |
| Van Dyke, TE | 1 |
| Lange, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial[NCT04554693] | Phase 4 | 90 participants (Anticipated) | Interventional | 2020-10-19 | Recruiting | ||
| Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization[NCT00707369] | Phase 4 | 540 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Effect of Non Surgical Therapy on Calprotectin and Periostin Levels in Patients With Periodontitis and Cardiovascular Diseases - An Interventional Study[NCT05618743] | 45 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | |||
| Fecal Microbiota Transplantation Versus Standard Medical Therapy for Initial Treatment of Recurrent Clostridium Difficile Infection[NCT02255305] | Phase 2 | 6 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to Due to personnel issues for finding and enrolling patients, performing appropriate follow-up and performing FMT procedure) | ||
| Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach[NCT00201422] | 70 participants (Actual) | Interventional | 1996-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients' length of stay post-procedure will be measured (NCT02255305)
Timeframe: 90 days
| Intervention | days (Mean) |
|---|---|
| FMT Group (Intervention Arm) | 22 |
| Antimicrobial Group (Control Arm) | 6.5 |
Number of patients who died from any cause within 90 days of randomization (NCT02255305)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| FMT Group (Intervention Arm) | 0 |
| Antimicrobial Group (Control Arm) | 0 |
Number of patients with resolution of diarrhea and other abdominal symptoms or return to baseline symptoms that were present prior to C. difficile diagnosis (NCT02255305)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| FMT Group (Intervention Arm) | 1 |
| Antimicrobial Group (Control Arm) | 0 |
Number of patients re-admitted to the hospital for recurrent Clostridium difficile infection (NCT02255305)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| FMT Group (Intervention Arm) | 1 |
| Antimicrobial Group (Control Arm) | 1 |
Amount of time it takes for patient to have cessation of diarrhea and abdominal pain/gastrointestinal symptoms (or return to baseline) and normalization of white blood cell count, creatinine, and temperature. (NCT02255305)
Timeframe: 90 days
| Intervention | days (Number) |
|---|---|
| FMT Group (Intervention Arm) | 44 |
8 reviews available for metronidazole and Disease Exacerbation
| Article | Year |
|---|---|
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2014 |
A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cholangitis, Sclerosing; | 2015 |
Clostridium difficile infection: clinical spectrum and approach to management.
Topics: Aminoglycosides; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Dietary Su | 2011 |
Rosacea. An overview of diagnosis and management.
Topics: Anti-Infective Agents; Body Image; Dermatologic Agents; Diagnosis, Differential; Dicarboxylic Acids; | 2004 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2007 |
Rosacea: how to recognize and treat an age-related skin disease.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Disease Progression; Humans; Laser Therapy; Metronid | 1997 |
Identifying and treating rosacea.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Diagnosis, Differential; Disease Progression; Drug The | 2001 |
Local antimicrobial therapies in periodontal disease.
Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Biocompatible Materials; Cell | 2000 |
6 trials available for metronidazole and Disease Exacerbation
| Article | Year |
|---|---|
Clinical and microbiologic effects of adjunctive metronidazole plus amoxicillin in the treatment of generalized chronic periodontitis: smokers versus non-smokers.
Topics: Actinomyces; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Periodontitis; Cohort Studies; Combi | 2014 |
Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2015 |
Calprotectin levels in gingival crevicular fluid predict disease activity in patients treated for generalized aggressive periodontitis.
Topics: Administration, Topical; Adult; Aggressive Periodontitis; Amoxicillin; Anti-Bacterial Agents; Anti-I | 2011 |
Clonal infection with Actinobacillus actinomycetemcomitans following periodontal therapy.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial Agents; Bacterial Outer Me | 1999 |
Repeated metronidazole and amoxicillin treatment of periodontitis. A follow-up study.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Anti-Infective Agents; Chronic Disease; Disease Prog | 2000 |
Aggressive periodontitis: 5-year follow-up of treatment.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial Agents; Dental Plaque; Den | 2002 |
29 other studies available for metronidazole and Disease Exacerbation
| Article | Year |
|---|---|
Exacerbation of Pediatric Periorificial Dermatitis: A Novel Adverse Reaction.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Boron Compounds; Bridged Bic | 2020 |
Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide.
Topics: Animals; Anti-Infective Agents; Chitosan; Disease Models, Animal; Disease Progression; Lactic Acid; | 2018 |
An unusual presentation of pulmonary embolism leading to infarction, cavitation, abscess formation and bronchopleural fistulation.
Topics: Abscess; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bronchial Fistula; Di | 2018 |
Conditional Demyelination and Remyelination in a Transgenic Xenopus laevis.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Disease Progression; Drug Evaluation | 2019 |
Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Disease Progression; Endometriosis; Endometr | 2019 |
Periodontal treatment prevents arthritis in mice and methotrexate ameliorates periodontal bone loss.
Topics: Alveolar Bone Loss; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Autoantibodies; Chlorhe | 2019 |
Endoscopic ultrasound-guided drainage of an amoebic liver abscess extending into the hepatic subcapsular space.
Topics: Adult; Antiparasitic Agents; Disease Progression; Drainage; Endosonography; Humans; Liver; Liver Abs | 2015 |
Broad-spectrum Antibiotic Plus Metronidazole May Not Prevent the Deterioration of Necrotizing Enterocolitis From Stage II to III in Full-term and Near-term Infants: A Propensity Score-matched Cohort Study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Case-Control Studies; Cohort Studies; Disease Progress | 2015 |
Parry-Romberg syndrome: a case with a possible association with Lyme disease.
Topics: Adolescent; Albania; Anti-Infective Agents; Borrelia burgdorferi; Disease Progression; Face; Facial | 2015 |
Vulvar inflammation: a presentation of Crohn's disease.
Topics: Adolescent; Adult; Antirheumatic Agents; Azathioprine; Biopsy; Colonoscopy; Crohn Disease; Disease P | 2017 |
Management of facial necrotizing fasciitis.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Clindamycin; Disease Progression; Drug Combinations | 2009 |
Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bacteroidaceae Infections; Cell Line; Cholesterol; Diet | 2009 |
[Phlegmon of the palm of the hand as initial manifestation of the Lemierre syndrome].
Topics: Abscess; Acromioclavicular Joint; Anti-Bacterial Agents; Cellulitis; Combined Modality Therapy; Diag | 2010 |
Coma in a 34-year-old with progressive changes on neuroimaging.
Topics: Adult; Coma; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Metronidazole; Nervous | 2010 |
[Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population].
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Disease Progression; Eye Diseases; Femal | 2011 |
An unusual cause of acute liver failure.
Topics: Aged, 80 and over; Contrast Media; Disease Progression; Drainage; Entamoeba histolytica; Fatal Outco | 2010 |
[A throat infection with rapid deterioration].
Topics: Abscess; Anti-Bacterial Agents; Diagnosis, Differential; Disease Progression; Drug Therapy, Combinat | 2002 |
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Chi-Square Distribution; Child; Clostridioides diffi | 2004 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Progression; Disease-Fre | 2005 |
[Clinical and histological study of lupoid cutaneous leishmaniasis (16 cases)].
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Biopsy; Child; Disease Progression; Female; | 2007 |
Distribution and genetic analysis of oral Prevotella intermedia and Prevotella nigrescens.
Topics: Adult; Age Factors; Aged; Bacterial Typing Techniques; Case-Control Studies; Child, Preschool; Disea | 1996 |
Putative periodontal pathogens, antibody titres and avidities to them in a longitudinal study of patients with resistant periodontitis.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Antibodies, Bacterial; Antibody Affinity; | 1996 |
Rapid progression of bone loss in HIV-associated necrotizing ulcerative stomatitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alveolar Bone Loss; Anti-Infective Agents; Anti-Infect | 1998 |
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Child; Disease Progression; Drug Th | 1999 |
Treatment considerations in rapidly progressive periodontitis: a case report.
Topics: Adult; Age of Onset; Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Colony Count, Micro | 1998 |
Periodontal treatment of rapid progressive periodontitis in 2 siblings with Papillon-Lefèvre syndrome: 15-year follow-up.
Topics: Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Anti-Bacterial Agents; Anti-Infecti | 2000 |
Effect of metronidazole on the pathogenicity of resistant Bacteroides strains in gnotobiotic mice.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides Infections; Disease Progression; Drug Resistance, Mi | 2000 |
A multidisciplinary approach to the diagnosis and treatment of early-onset periodontitis: a case report.
Topics: Adolescent; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Amoxicillin; Anti-Bacte | 2001 |
The effect of systemic antibiotics in the treatment of patients with recurrent periodontitis.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Amoxicillin; Anti-Bacterial Agents | 2001 |